Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus

AstraZeneca drug cocktail succeeds in late-stage study to treat Covid-19

Chidinma Anyalewechi by Chidinma Anyalewechi
October 12, 2021
in Coronavirus
AstraZeneca drug cocktail succeeds in late-stage study to treat Covid-19

AstraZeneca Tablets At A Pharmacists As Company Explores Deal With Acerta Pharma...Packets of Nexium, manufactured AstraZeneca Plc, sit on a table at a pharmacists in this arranged photograph in London, U.K., on Monday, Dec. 14, 2015. AstraZeneca Plc said it's exploring a deal with Acerta Pharma BV that would give the U.K. drugmaker a potential blockbuster medicine for blood cancers as well as diseases in which the body attacks itself. Photographer: Simon Dawson/Bloomberg

Share on FacebookShare on TwitterShare on Linkedin

In a late-stage study, AstraZeneca’s experimental Covid-19 antibody drug cocktail has succeeded in reducing severe disease or death in non-hospitalized patients, the British drugmaker said on Monday.

Similar to the results obtained with the Merck antiviral pills, the Astrazeneca drug, called AZD7442, has proven to reduce the risk of developing severe Covid-19 or death by 50%, in patients who had been symptomatic for seven days or less, meeting the main goal of the trial, according to CNBC.

The success of this drug cocktail and the Merck antiviral pills have been described as a huge breakthrough, considering the devastating effect the Coronavirus has had on the global space this time last year.

RelatedPosts

World Bank says COVID-19 sparked surge in financial inclusion globally

US Vice President, Kamala Harris tests positive for COVID-19

What they are saying

The executive vice president, biopharmaceuticals R&D at AstraZeneca, Mene Pangalos, said, “an early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months.”

He further stated that the company will discuss all available data with health authorities.

News continues after this ad


The drugmaker has requested emergency approval of its drug cocktail from U.S regulators for its use as a prevention drug last week. The drug cocktail is also being developed to serve as a therapy to protect people who do not have a strong enough immune response to Covid-19 vaccines.

In addition, AstraZeneca’s therapy is the first of its kind to show positive potential as preventative medicine and as a treatment for COVID-19 following multiple trials and these therapies have been approved for emergency use in the United States for treating mild-to-moderate COVID-19.

News continues after this ad


The trial Principal investigator, Hugh Montgomery said in a statement that, “These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic”.

Related

Tags: AstraZenecaAZD7442Covid-19

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

inq
avatrade
Stanbic bank
Mega Millions
UBN
Hot forex
Access Bank
Bankers Committee
First bank






    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    • Confusion as NUPRC rejects approval of Seplat and Mobil deal hours after President Buhari approved
    • Sell-offs from MTN causes market to dip by N125 billion
    • Crypto-mixing service, Tornado Cash, blacklisted in the United States 

    Follow us on social media:

    Recent News

    Nigeria loses $4 billion annually to oil theft  – NUPRC

    Confusion as NUPRC rejects approval of Seplat and Mobil deal hours after President Buhari approved

    August 8, 2022
    Weekly Stock Update: Nigerian local bourse’s ASI depreciates by 0.22% w-o-w

    Sell-offs from MTN causes market to dip by N125 billion

    August 8, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Financial Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Metrics
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
      • Securities
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
      • Real Estate and Construction
      • Tech News
    • Economy
      • Get Data
      • Macro-Economic News
      • Research Analysis
    • Business News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com